Patents by Inventor Shoichi Naito
Shoichi Naito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11136411Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: November 18, 2019Date of Patent: October 5, 2021Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Hiroaki Aino, Etsuo Nakamura, Sunao Imai, Shoji Yamane
-
Patent number: 10745491Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: January 11, 2019Date of Patent: August 18, 2020Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Publication number: 20200071424Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: November 18, 2019Publication date: March 5, 2020Applicant: Shionogi & Co., Ltd.Inventors: Shoichi NAITO, Hiroaki AINO, Etsuo NAKAMURA, Sunao IMAI, Shoji YAMANE
-
Patent number: 10570215Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: March 10, 2017Date of Patent: February 25, 2020Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Hiroaki Aino, Etsuo Nakamura, Sunao Imai, Shoji Yamane
-
Publication number: 20190211114Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: January 11, 2019Publication date: July 11, 2019Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 10239955Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: June 2, 2017Date of Patent: March 26, 2019Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Publication number: 20170275378Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: June 2, 2017Publication date: September 28, 2017Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Publication number: 20170260290Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: March 10, 2017Publication date: September 14, 2017Applicant: Shionogi & Co., Ltd.Inventors: Shoichi NAITO, Hiroaki AINO, Etsuo NAKAMURA, Sunao IMAI, Shoji YAMANE
-
Patent number: 9701757Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: March 12, 2014Date of Patent: July 11, 2017Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Patent number: 9296825Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: October 11, 2012Date of Patent: March 29, 2016Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Publication number: 20160009819Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: March 12, 2014Publication date: January 14, 2016Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Publication number: 20150025225Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: October 11, 2012Publication date: January 22, 2015Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Patent number: 8883977Abstract: An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.Type: GrantFiled: April 28, 2011Date of Patent: November 11, 2014Assignees: Shionogi & Co., Ltd., National University Corporation Hokkaido UniversityInventors: Shin-Ichiro Nishimura, Shoichi Naito, Naoki Ohyabu, Tatsuya Takahashi, Yoshito Numata, Keiko Kawamoto
-
Patent number: 8722856Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.Type: GrantFiled: October 28, 2009Date of Patent: May 13, 2014Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
-
Patent number: 8536313Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: GrantFiled: July 8, 2008Date of Patent: September 17, 2013Assignee: Shionogi & Co., Ltd.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Publication number: 20130045543Abstract: An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.Type: ApplicationFiled: April 28, 2011Publication date: February 21, 2013Inventors: Shin-Ichiro Nishimura, Shoichi Naito, Naoki Ohyabu, Tatsuya Takahashi, Yoshito Numata
-
Publication number: 20120040375Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.Type: ApplicationFiled: October 28, 2009Publication date: February 16, 2012Applicants: SHIONOGI & CO., LTD.Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
-
Publication number: 20100330092Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: ApplicationFiled: July 8, 2008Publication date: December 30, 2010Applicant: SHIONLGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono